{
    "info": {
        "nct_id": "NCT04535271",
        "official_title": "TAGGED: A Phase 2 Study Using Low Dose/Metronomic Trabectedin, Gemcitabine, and Dacarbazine as 2nd/3rd/4th Line Therapy for Advanced Soft Tissue Sarcoma",
        "inclusion_criteria": "* Male or Female ≥ 18 years of age\n* Pathologically confirmed diagnosis of locally advanced, unresectable or metastatic leiomyosarcoma\n* Previously treated patient with measurable disease by RECIST v1.1\n* ECOG performance status ≤ 2\n* Life expectancy of at least 3 months\n* Acceptable liver function: Bilirubin < 1.5 times upper limit of normal (ULN; except subjects with Gilbert Syndrome who must have a total bilirubin level < 3.0 ULN); AST (SGOT), ALT (SGPT) and alk phos < 2.5 x ULN (< 5 x ULN if liver metastases present)\n* Acceptable renal function: Creatinine < 1.5 times ULN and creatinine clearance > 60 ml/min using the Crockroft-Gault formula\n* Acceptable hematologic status: ANC >1000 cells/μL; Platelet count >100,000/μL; Hemoglobin > 9.0 g/dL\n* INR and PT < 1.5 ULN unless taking anti-coagulation, in which case PT, INR and aPTT must be within therapeutic range of intended use of anticoagulants\n* Ability to understand the purposes and risks of the study and has signed and dated a written informed consent form approved by the Investigator's IRB/Ethics Committee\n* Willingness to comply with all study procedures and availability for the duration of the study\n* All women of childbearing potential must have a negative urine or serum pregnancy test within 72 hours of enrollment. If urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; all subjects must agree to use highly effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 5 months for women and 7 months for men after the last dose.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Currently receiving treatment with another investigational device or drug study, or <14 days since ending treatment with another investigational device or drug study(s).\n* Subject has known sensitivity to trabectedin, gemcitabine or dacarbazine.\n* Female subject is pregnant or breast-feeding or planning to become pregnant during study treatment and through 3 months after the last dose of trabectedin, gemcitabine or dacarbazine.\n* Female subject of childbearing potential who is unwilling to use acceptable method(s) of effective contraception during study treatment and through 3 months after the last dose of trabectedin, gemcitabine or dacarbazine.\n* Sexually active subjects and their partners unwilling to use male or female latex condom",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Previously treated patient with measurable disease by RECIST v1.1",
            "criterions": [
                {
                    "exact_snippets": "Previously treated patient",
                    "criterion": "prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "measurable disease by RECIST v1.1",
                    "criterion": "measurable disease (by RECIST v1.1)",
                    "requirements": [
                        {
                            "requirement_type": "measurability (RECIST v1.1)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* INR and PT < 1.5 ULN unless taking anti-coagulation, in which case PT, INR and aPTT must be within therapeutic range of intended use of anticoagulants",
            "criterions": [
                {
                    "exact_snippets": "INR and PT < 1.5 ULN unless taking anti-coagulation",
                    "criterion": "INR",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "INR and PT < 1.5 ULN unless taking anti-coagulation",
                    "criterion": "PT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless taking anti-coagulation, in which case PT, INR and aPTT must be within therapeutic range of intended use of anticoagulants",
                    "criterion": "PT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "within therapeutic range of intended use of anticoagulants"
                        }
                    ]
                },
                {
                    "exact_snippets": "unless taking anti-coagulation, in which case PT, INR and aPTT must be within therapeutic range of intended use of anticoagulants",
                    "criterion": "INR",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "within therapeutic range of intended use of anticoagulants"
                        }
                    ]
                },
                {
                    "exact_snippets": "unless taking anti-coagulation, in which case PT, INR and aPTT must be within therapeutic range of intended use of anticoagulants",
                    "criterion": "aPTT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "within therapeutic range of intended use of anticoagulants"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status ≤ 2",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status ≤ 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male or Female ≥ 18 years of age",
            "criterions": [
                {
                    "exact_snippets": "Male or Female",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "≥ 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to understand the purposes and risks of the study and has signed and dated a written informed consent form approved by the Investigator's IRB/Ethics Committee",
            "criterions": [
                {
                    "exact_snippets": "Ability to understand the purposes and risks of the study",
                    "criterion": "ability to understand study purposes and risks",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has signed and dated a written informed consent form approved by the Investigator's IRB/Ethics Committee",
                    "criterion": "signed and dated written informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "approval",
                            "expected_value": "Investigator's IRB/Ethics Committee"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Acceptable renal function: Creatinine < 1.5 times ULN and creatinine clearance > 60 ml/min using the Crockroft-Gault formula",
            "criterions": [
                {
                    "exact_snippets": "Creatinine < 1.5 times ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "times ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "creatinine clearance > 60 ml/min using the Crockroft-Gault formula",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 60,
                                "unit": "ml/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Crockroft-Gault formula"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy of at least 3 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of at least 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pathologically confirmed diagnosis of locally advanced, unresectable or metastatic leiomyosarcoma",
            "criterions": [
                {
                    "exact_snippets": "Pathologically confirmed diagnosis",
                    "criterion": "diagnosis confirmation",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathological"
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced, unresectable or metastatic leiomyosarcoma",
                    "criterion": "leiomyosarcoma",
                    "requirements": [
                        {
                            "requirement_type": "disease stage",
                            "expected_value": [
                                "locally advanced",
                                "unresectable",
                                "metastatic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Acceptable liver function: Bilirubin < 1.5 times upper limit of normal (ULN; except subjects with Gilbert Syndrome who must have a total bilirubin level < 3.0 ULN); AST (SGOT), ALT (SGPT) and alk phos < 2.5 x ULN (< 5 x ULN if liver metastases present)",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin < 1.5 times upper limit of normal (ULN; except subjects with Gilbert Syndrome who must have a total bilirubin level < 3.0 ULN)",
                    "criterion": "bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "quantity (Gilbert Syndrome exception)",
                            "expected_value": {
                                "operator": "<",
                                "value": 3.0,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST (SGOT), ALT (SGPT) and alk phos < 2.5 x ULN (< 5 x ULN if liver metastases present)",
                    "criterion": "AST (SGOT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "quantity (if liver metastases present)",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST (SGOT), ALT (SGPT) and alk phos < 2.5 x ULN (< 5 x ULN if liver metastases present)",
                    "criterion": "ALT (SGPT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "quantity (if liver metastases present)",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST (SGOT), ALT (SGPT) and alk phos < 2.5 x ULN (< 5 x ULN if liver metastases present)",
                    "criterion": "alkaline phosphatase level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "quantity (if liver metastases present)",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Acceptable hematologic status: ANC >1000 cells/μL; Platelet count >100,000/μL; Hemoglobin > 9.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "ANC >1000 cells/μL",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1000,
                                "unit": "cells/μL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Platelet count >100,000/μL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 100000,
                                "unit": "/μL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Hemoglobin > 9.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willingness to comply with all study procedures and availability for the duration of the study",
            "criterions": [
                {
                    "exact_snippets": "Willingness to comply with all study procedures",
                    "criterion": "willingness to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "availability for the duration of the study",
                    "criterion": "availability for the duration of the study",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All women of childbearing potential must have a negative urine or serum pregnancy test within 72 hours of enrollment. If urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; all subjects must agree to use highly effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 5 months for women and 7 months for men after the last dose.",
            "criterions": [
                {
                    "exact_snippets": "All women of childbearing potential must have a negative urine or serum pregnancy test within 72 hours of enrollment.",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "test type",
                            "expected_value": [
                                "urine pregnancy test",
                                "serum pregnancy test"
                            ]
                        },
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 72,
                                "unit": "hours before enrollment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "all subjects must agree to use highly effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 5 months for women and 7 months for men after the last dose.",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception methods",
                            "expected_value": [
                                "surgical sterilization",
                                "barrier contraception with condom",
                                "barrier contraception with diaphragm",
                                "barrier contraception with spermicidal gel",
                                "IUD"
                            ]
                        },
                        {
                            "requirement_type": "duration (women)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "months after last dose"
                            }
                        },
                        {
                            "requirement_type": "duration (men)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "months after last dose"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Subject has known sensitivity to trabectedin, gemcitabine or dacarbazine.",
            "criterions": [
                {
                    "exact_snippets": "Subject has known sensitivity to trabectedin",
                    "criterion": "sensitivity to trabectedin",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subject has known sensitivity to ... gemcitabine",
                    "criterion": "sensitivity to gemcitabine",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subject has known sensitivity to ... dacarbazine",
                    "criterion": "sensitivity to dacarbazine",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Currently receiving treatment with another investigational device or drug study, or <14 days since ending treatment with another investigational device or drug study(s).",
            "criterions": [
                {
                    "exact_snippets": "Currently receiving treatment with another investigational device or drug study",
                    "criterion": "treatment with another investigational device or drug study",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "<14 days since ending treatment with another investigational device or drug study(s)",
                    "criterion": "time since ending treatment with another investigational device or drug study",
                    "requirements": [
                        {
                            "requirement_type": "time since ending",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Sexually active subjects and their partners unwilling to use male or female latex condom",
            "criterions": [
                {
                    "exact_snippets": "Sexually active subjects",
                    "criterion": "sexual activity",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unwilling to use male or female latex condom",
                    "criterion": "condom use willingness",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female subject is pregnant or breast-feeding or planning to become pregnant during study treatment and through 3 months after the last dose of trabectedin, gemcitabine or dacarbazine.",
            "criterions": [
                {
                    "exact_snippets": "Female subject is pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breast-feeding",
                    "criterion": "breast-feeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "planning to become pregnant during study treatment and through 3 months after the last dose of trabectedin, gemcitabine or dacarbazine",
                    "criterion": "pregnancy intention during and after treatment",
                    "requirements": [
                        {
                            "requirement_type": "intention to become pregnant",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": "during study treatment and through 3 months after the last dose of trabectedin, gemcitabine or dacarbazine"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female subject of childbearing potential who is unwilling to use acceptable method(s) of effective contraception during study treatment and through 3 months after the last dose of trabectedin, gemcitabine or dacarbazine.",
            "criterions": [
                {
                    "exact_snippets": "Female subject of childbearing potential",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unwilling to use acceptable method(s) of effective contraception during study treatment and through 3 months after the last dose of trabectedin, gemcitabine or dacarbazine",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during study treatment and through 3 months after the last dose of trabectedin, gemcitabine or dacarbazine"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}